[Cyclosporin A in atopic dermatitis].
Atopic dermatitis is a chronic inflammatory skin disease, with inherited predisposition. It has typical morphology and distribution. Patients generally can be controlled with the use of moisturizers and topical steroids. In severe cases, it is recommended the use of alternative management. Cyclosporine is an immunosuppressor drug which inhibit the expression of T activated cells. Many open and placebo-controlled trials have been made evaluating its use, efficacy and security, in adults and children. The results suggest an initial dose of 5-6 mg/kg per day and reducing the amount according to response (load dose and maintenance dose) at long term in order to reach complete remission after withdrawal of treatment and limit adverse effects, like renal toxicity and hypertension. The immunological changes in AD patients treated with cyclosporine include eosinophil count reduction, besides lower levels of E-selectin, and soluble CD30 (known as disease markers), but overall, it corrects the imbalance between Th1 and Th2 response present in these kinds of diseases.
Cordero Miranda
Miguel Angel
MA
Servicio de alergia, Médico pediatra, Hospital Infantil de México Federico Gómez, México, DF.
Casas Becerra
Begonia
B
Reyes Ruiz
Norma Isabel
NI
Avila Castañón
Lourdes
L
del Río Navarro
Blanca Estela
BE
Sienra Monge
Juan José Luis
JJ
D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced; D008213:Lymphocyte Activation / Q000187:drug effects; D015337:Multicenter Studies as Topic; D013601:T-Lymphocytes / Q000187:drug effects
D016207:Cytokines; D007166:Immunosuppressive Agents; D016572:Cyclosporine